Sekar Kathiresan - Feb 11, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Feb 11, 2022
Transactions value $
$0
Form type
4
Date filed
2/15/2022, 07:58 AM
Previous filing
Jan 6, 2022
Next filing
Mar 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +332K $0.00 332K Feb 11, 2022 Common Stock 332K $30.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 11, 2022. 25% of the shares underlying the option will vest on February 11, 2023, and the remainder are scheduled to vest in equal monthly installments thereafter until February 11, 2026.